Jove
Visualize
Contact Us

Related Concept Videos

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

336
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
336
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

151
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These...
151
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Enrofloxacin Pharmaceutical Formulations Through The Polymer-free Electrospinning Of Β-cyclodextrin-oligolactide Derivatives.
  1. Home
  3. Enrofloxacin Pharmaceutical Formulations Through The Polymer-free Electrospinning Of Β-cyclodextrin-oligolactide Derivatives.

Related Experiment Video

Fabricating Superhydrophobic Polymeric Materials for Biomedical Applications
09:22

Fabricating Superhydrophobic Polymeric Materials for Biomedical Applications

Published on: August 28, 2015

19.1K

Enrofloxacin Pharmaceutical Formulations through the Polymer-Free Electrospinning of β-Cyclodextrin-oligolactide

Diana-Andreea Blaj1,2, Cătălina Anișoara Peptu2, Maricel Danu2

  • 1"Petru Poni" Institute of Macromolecular Chemistry, 700487 Iasi, Romania.

Pharmaceutics
|July 27, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

New drug formulations enhance enrofloxacin (ENR) delivery using cyclodextrin-oligolactide (CDLA) derivatives. These novel electrospun nanofibers maintain ENR

Keywords:
antibacterial activitycyclodextrin–oligolactideelectrospinningenrofloxacinnanofibers

More Related Videos

Fabricating Degradable Thermoresponsive Hydrogels on Multiple Length Scales via Reactive Extrusion, Microfluidics, Self-assembly, and Electrospinning
12:07

Fabricating Degradable Thermoresponsive Hydrogels on Multiple Length Scales via Reactive Extrusion, Microfluidics, Self-assembly, and Electrospinning

Published on: April 16, 2018

13.4K
Vapor Phase Deposition of Electroactive Poly(3,4-ethylenedioxythiophene) onto Electrospun Commodity Polymer Nanofibers
08:28

Vapor Phase Deposition of Electroactive Poly(3,4-ethylenedioxythiophene) onto Electrospun Commodity Polymer Nanofibers

Published on: March 7, 2025

761

Related Experiment Videos

Fabricating Superhydrophobic Polymeric Materials for Biomedical Applications
09:22

Fabricating Superhydrophobic Polymeric Materials for Biomedical Applications

Published on: August 28, 2015

19.1K
Fabricating Degradable Thermoresponsive Hydrogels on Multiple Length Scales via Reactive Extrusion, Microfluidics, Self-assembly, and Electrospinning
12:07

Fabricating Degradable Thermoresponsive Hydrogels on Multiple Length Scales via Reactive Extrusion, Microfluidics, Self-assembly, and Electrospinning

Published on: April 16, 2018

13.4K
Vapor Phase Deposition of Electroactive Poly(3,4-ethylenedioxythiophene) onto Electrospun Commodity Polymer Nanofibers
08:28

Vapor Phase Deposition of Electroactive Poly(3,4-ethylenedioxythiophene) onto Electrospun Commodity Polymer Nanofibers

Published on: March 7, 2025

761

Area of Science:

  • Veterinary Pharmacology
  • Drug Delivery Systems
  • Nanotechnology

Background:

  • Enrofloxacin (ENR), a fluoroquinolone antibiotic, faces challenges with poor water solubility and low bioavailability in veterinary applications.
  • Existing formulation strategies like solid dispersions and nanosuspensions have limitations.
  • Novel approaches are needed to improve ENR's therapeutic efficacy.

Purpose of the Study:

  • To develop novel enrofloxacin (ENR) formulations using custom-prepared cyclodextrin-oligolactide (CDLA) derivatives.
  • To investigate the feasibility of polymer-free co-electrospinning of ENR with CDLA derivatives.
  • To evaluate the antibacterial efficacy of the developed ENR-CDLA formulations.

Main Methods:

  • Co-electrospinning of enrofloxacin (ENR) with custom-prepared cyclodextrin-oligolactide (CDLA) derivatives.
  • Optimization of electrospinning parameters for high ENR incorporation into nanofibrous webs.
  • Characterization using FTIR and NMR spectroscopy.
  • In vitro antibacterial activity testing against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.

    • Main Results:

    • Successful development of polymer-free ENR-loaded CDLA nanofibrous webs via co-electrospinning.
    • Achieved significant ENR incorporation, up to 15.6% by weight, into the nanofibrous formulations.
    • Characterization confirmed the successful integration of ENR within the CDLA matrix.
    • Demonstrated retained antibacterial activity of ENR against tested bacterial strains.

    Conclusions:

    • Co-electrospinning of enrofloxacin (ENR) with cyclodextrin-oligolactide (CDLA) derivatives is a viable method for creating advanced drug delivery systems.
    • The developed ENR-CDLA nanofibrous formulations effectively incorporate high drug loads without compromising antibacterial activity.
    • These formulations show promise for improved veterinary antibiotic therapy and warrant further investigation.